7 Proven Steps to Choosing a Bioanalytical CRO for Global Drug Development
Running a global program? Here’s how to choose a bioanalytical CRO for global drug development, from lab footprint to phase-to-phase handoffs.
Running a global program? Here’s how to choose a bioanalytical CRO for global drug development, from lab footprint to phase-to-phase handoffs.
Resolian’s Analytical Sciences team developed a simplified, USP-aligned system suitability test mixture for non-targeted LC-HRAMS extractables and leachables screening, reducing component count from fifteen to fewer than ten while maintaining coverage of all key USP stimulus attributes.
Resolian developed and validated an MSD-based bridging ECLIA method for analysing anti-drug antibodies against a GalNAc-conjugated siRNA therapeutic, evaluating both MSD and Gyrolab platforms for different GalNAc-conjugated siRNA therapeutics and providing a practical framework for immunogenicity assay development in this novel modality.
Resolian developed high-precision LC-MS/MS methods and optimised equilibrium dialysis workflows for plasma protein binding assessment of highly protein-bound compounds, Supporting ICH M12 regulatory expectations across five species.
Take a virtual tour of Resolian’s Sandwich lab: analytical and materials science expertise spanning solid state, physical properties, and foreign matter analysis.
Resolian developed and validated (following ICH-M10) a high-throughput and robust LC MS/MS method for quantifying intact carboplatin in human plasma, overcoming long-standing challenges around isotopic interference, protein binding, and chromatographic retention.
How does milling method affect pharmaceutical powder surfaces? Resolian’s iGC-SEA analysis of sucrose reveals that processing route influences surface energy more significantly than particle size alone.
Discover how Resolian used iGC-SEA to characterise polymer nanoparticle surface energy for Loughborough University, generating new insights into protein corona formation and nanomedicine development.
USP 665 and USP 1665 are now mandatory for pharma and biopharma manufacturers using plastic components. Learn what compliance requires and how Resolian’s E&L experts can help.
How do you evaluate a CRO beyond price? This guide covers technical capabilities, quality systems, geographical reach, and partnership factors that matter most.